POSTER PRESENTATIONS: Posters Saturday, 22 April 2017: Viral hepatitis: Hepatitis C – Clinical (therapy)
SAT-280 - SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies

https://doi.org/10.1016/S0168-8278(17)31974-8Get rights and content

References (0)

Cited by (0)

View full text